1. Home
  2. CELC vs TWFG Comparison

CELC vs TWFG Comparison

Compare CELC & TWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • TWFG
  • Stock Information
  • Founded
  • CELC 2011
  • TWFG 2001
  • Country
  • CELC United States
  • TWFG United States
  • Employees
  • CELC N/A
  • TWFG N/A
  • Industry
  • CELC Medical Specialities
  • TWFG
  • Sector
  • CELC Health Care
  • TWFG
  • Exchange
  • CELC Nasdaq
  • TWFG NYSE
  • Market Cap
  • CELC 440.0M
  • TWFG 521.8M
  • IPO Year
  • CELC 2017
  • TWFG 2024
  • Fundamental
  • Price
  • CELC $13.77
  • TWFG $31.00
  • Analyst Decision
  • CELC Strong Buy
  • TWFG Buy
  • Analyst Count
  • CELC 6
  • TWFG 8
  • Target Price
  • CELC $30.67
  • TWFG $35.57
  • AVG Volume (30 Days)
  • CELC 245.9K
  • TWFG 95.8K
  • Earning Date
  • CELC 08-13-2025
  • TWFG 08-12-2025
  • Dividend Yield
  • CELC N/A
  • TWFG N/A
  • EPS Growth
  • CELC N/A
  • TWFG N/A
  • EPS
  • CELC N/A
  • TWFG N/A
  • Revenue
  • CELC N/A
  • TWFG $211,440,000.00
  • Revenue This Year
  • CELC N/A
  • TWFG $23.90
  • Revenue Next Year
  • CELC N/A
  • TWFG $22.60
  • P/E Ratio
  • CELC N/A
  • TWFG N/A
  • Revenue Growth
  • CELC N/A
  • TWFG 18.57
  • 52 Week Low
  • CELC $7.58
  • TWFG $21.80
  • 52 Week High
  • CELC $19.77
  • TWFG $36.85
  • Technical
  • Relative Strength Index (RSI)
  • CELC 59.12
  • TWFG N/A
  • Support Level
  • CELC $13.47
  • TWFG N/A
  • Resistance Level
  • CELC $14.57
  • TWFG N/A
  • Average True Range (ATR)
  • CELC 0.65
  • TWFG 0.00
  • MACD
  • CELC -0.04
  • TWFG 0.00
  • Stochastic Oscillator
  • CELC 36.65
  • TWFG 0.00

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About TWFG TWFG INC

TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.

Share on Social Networks: